TransMedics (TMDX) Research & Development (2018 - 2026)

TransMedics' Research & Development history runs 9 years deep, the most recent figure standing at $24.9 million for Q1 2026.

• In Q1 2026, Research & Development rose 44.98% year-over-year to $24.9 million; the TTM figure through Mar 2026 stood at $76.8 million (up 24.33% YoY), while the FY2025 annual figure was $69.1 million, up 23.38% from the prior year.
• Research & Development was $24.9 million for Q1 2026 at TransMedics, up from $20.7 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $24.9 million in Q1 2026 to a low of $5.8 million in Q4 2022.
• Historically, Research & Development has averaged $12.5 million across 5 years, with a median of $11.4 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Research & Development decreased 22.07% in 2023, then jumped 93.83% in 2024.
• A 5-year view of Research & Development shows it stood at $5.8 million in 2022, then soared by 86.95% to $10.8 million in 2023, then jumped by 53.0% to $16.5 million in 2024, then climbed by 25.73% to $20.7 million in 2025, then gained by 20.18% to $24.9 million in 2026.
• The last three Research & Development figures came in at $24.9 million (Q1 2026), $20.7 million (Q4 2025), and $15.3 million (Q3 2025), per Business Quant data.